From SOCE Blockade to Fibrosis Translation
2026-09-01
YM 58483 (BTP2) offers a practical pharmacologic lens on sustained calcium influx, linking immune-cell activation assays with emerging evidence in radiation-associated salivary gland fibrosis. This thought-leadership guide translates mechanism into experimental strategy while defining the boundaries between useful hypothesis generation and clinical interpretation.
GKT137831: Dual Nox1/Nox4 Inhibitor Workflows
2026-09-01
GKT137831 enables source-directed inhibition of Nox1/Nox4 rather than broad antioxidant treatment, supporting vascular, fibrotic, and metabolic disease models. This practical guide connects redox-control experiments with ferroptosis-focused assays while clearly separating established evidence from testable extensions.
CCT007093: A Practical PPM1D Inhibitor Guide
2026-08-31
CCT007093 is a DMSO-soluble PPM1D inhibitor for connecting phosphatase activity with p38 signaling, cancer-cell responses, and inflammatory kidney injury. This workflow-oriented guide shows how to formulate, dose, validate, and troubleshoot the compound across biochemical, cellular, and pyroptosis assays.
Ro 3306: CDK1 Inhibitor Workflow Guide
2026-08-30
Ro 3306 provides reversible control of CDK1 activity for cell cycle G2/M phase arrest, cancer cell synchronization, and checkpoint analysis. Its value extends to phase-resolved mTORC1, autophagy, and DNA repair experiments when treatment timing is paired with orthogonal validation.
Bradykinin B2 Receptors and Ileal Peristalsis
2026-08-29
Chan and Rudd showed that bradykinin inhibits the peristaltic reflex in the isolated guinea pig ileum through bradykinin B2 receptors rather than B1 receptors. Their pressure-threshold assay, combined with selective agonists and antagonists, provides a useful pharmacological framework for separating direct smooth-muscle effects from coordinated enteric motor responses.
Allosteric PDK4 Inhibitors for Metabolic Disease
2026-08-29
The 2019 Journal of Medicinal Chemistry study identified a new anthraquinone-derived series of allosteric pyruvate dehydrogenase kinase 4 inhibitors, led by compound 8c with an in vitro IC50 of 84 nM. Its metabolic stability, pharmacokinetic characterization, glucose-tolerance data, allergy-model activity, and cancer-related cellular findings establish a useful preclinical framework while leaving important questions about selectivity, target engagement, and clinical translation.
Elobixibat hydrate: Reliable Assay Workflows
2026-08-28
Learn how Elobixibat hydrate (SKU C8720) can be incorporated into reproducible cell viability, proliferation, and cytotoxicity workflows while avoiding solvent, precipitation, and interpretation errors. This scenario-based guide connects IBAT biology with practical assay controls and evidence-informed product selection.
EZ Cap™ Cy5 EGFP mRNA (5-moUTP) Guide
2026-08-28
Use dual fluorescence to separate mRNA uptake from functional EGFP translation in delivery screens. This practical guide applies the reporter to macrophage-targeted nanoparticles, quantitative transfection studies, and assay troubleshooting.
Sodium Ascorbate in Cell Assay Workflows
2026-08-27
Learn how Sodium Ascorbate, SKU B1834, can support controlled ROS, viability, proliferation, and cytotoxicity studies in cancer models. This scenario-based guide covers formulation compatibility, protocol optimization, interpretation, vendor selection, and evidence-based limitations.
β-Elemene Inhibits 3T3-L1 Adipogenesis via AMPK
2026-08-27
The reference study shows that β-Elemene suppresses MDI-induced lipid accumulation in 3T3-L1 preadipocytes and improves glucose consumption in a dexamethasone-induced insulin-resistance model. Its main contribution is to connect these metabolic effects with restoration of AMPK pathway activity, providing a mechanistic basis for further cellular obesity research.
MFGE8 Nanomedicine for Pancreatic Fibrosis
2026-08-26
This study presents a multimodal strategy in which umbilical cord-derived mesenchymal stem cells, their extracellular vesicles, and recombinant MFGE8 nanoparticles reduce pancreatic injury and fibrosis. Its central mechanistic contribution is the identification of an MFGE8-dependent ANXA1-SMAD2/3 axis in pancreatic stellate cells, providing a rationale for cell-free antifibrotic therapy.
Capsaicin Workflows for TRPV1 and KDM1A Research
2026-08-26
Capsaicin enables a distinctive two-axis workflow: rapid TRPV1 signaling assays can be paired with slower KDM1A/LSD1-dependent cancer and inflammation readouts. This guide translates that dual activity into practical cell, neuron, biochemical, and animal-model experiments with solvent, timing, and interpretation controls.
Elobixibat Hydrate: Translational IBAT Strategy
2026-08-25
A mechanism-first guide to using Elobixibat hydrate in gastrointestinal, metabolic, and translational research, linking IBAT inhibition to assay design, clinical relevance, and strategic development decisions.
Pomalidomide: A Mutation-Aware Myeloma Assay Strategy
2026-08-25
Pomalidomide (CC-4047) can do more than suppress inflammatory signaling in multiple myeloma research: it can serve as a probe for genotype-dependent tumor biology. This article connects mutationally diverse cell-line selection with tumor microenvironment modulation, layered readouts, and translational assay limits.
Cy7 NHS Ester: Practical Labeling Guide
2026-08-24
Cy7 NHS ester (A8109) is a water-compatible amino-group labeling reagent for preparing near-infrared fluorescent protein, peptide, and other biomolecule conjugates. It is useful for controlled in vitro or in vivo imaging workflows, but it should not be treated as evidence of cellular uptake, target specificity, safety, or preserved biomolecule function without application-specific validation.
466 records 7/32 page Previous Next First page 上5页 678910 下5页 Last page